Detalles de la búsqueda
1.
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Ann Oncol;
34(12): 1131-1140, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38072513
2.
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Ann Oncol;
34(12): 1141-1151, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38072514
3.
Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
Climacteric;
22(1): 65-72, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30554531
4.
Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.
Climacteric;
18(2): 226-32, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25252699
5.
Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
Climacteric;
18(4): 590-607, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25511551
6.
Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society.
Climacteric;
17(5): 557-63, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25153131
7.
Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.
Climacteric;
17(2): 173-82, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23984673
8.
Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
Maturitas;
79(3): 349-54, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25179577
Resultados
1 -
8
de 8
1
Próxima >
>>